A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
M Sebastian, A Schröder, B Scheel, HS Hong… - Cancer immunology …, 2019 - Springer
CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung
cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen …
cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen …
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation …
A Papachristofilou, MM Hipp, U Klinkhardt… - … for immunotherapy of …, 2019 - Springer
Background Preclinical studies demonstrate synergism between cancer immunotherapy and
local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 …
local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 …
A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with …
HA Burris, MR Patel, DC Cho, JM Clarke, M Gutierrez… - 2019 - ascopubs.org
2523 Background: T-cell targeting of mutation-derived epitopes (neoantigens) has been
demonstrated to drive anti-tumor responses. Immunizing patients against such neoantigens …
demonstrated to drive anti-tumor responses. Immunizing patients against such neoantigens …
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
M Fotin‐Mleczek, K Zanzinger… - The journal of gene …, 2012 - Wiley Online Library
Direct vaccination with mRNA encoding tumor antigens is a novel and promising approach
in cancer immunotherapy. CureVac's mRNA vaccines contain free and protamine …
in cancer immunotherapy. CureVac's mRNA vaccines contain free and protamine …
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for …
M Sebastian, A Papachristofilou, C Weiss, M Früh… - BMC cancer, 2014 - Springer
Background Advanced non-small cell lung cancer (NSCLC) represents a significant unmet
medical need. Despite advances with targeted therapies in a small subset of patients, fewer …
medical need. Despite advances with targeted therapies in a small subset of patients, fewer …
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non–small-cell lung …
M Barve, J Bender, N Senzer… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Generation of broad cytotoxic T-lymphocyte responses against multiple epitopes
and tumor-associated antigens (TAAs) may provide effective immunotherapy in patients with …
and tumor-associated antigens (TAAs) may provide effective immunotherapy in patients with …
The use of RNA-based treatments in the field of cancer immunotherapy
M Chehelgerdi, M Chehelgerdi - Molecular Cancer, 2023 - Springer
Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …
mRNA in cancer immunotherapy: beyond a source of antigen
L Van Hoecke, R Verbeke, H Dewitte, I Lentacker… - Molecular cancer, 2021 - Springer
Abstract mRNA therapeutics have become the focus of molecular medicine research.
Various mRNA applications have reached major milestones at high speed in the immuno …
Various mRNA applications have reached major milestones at high speed in the immuno …
Advances and prospects of mRNA vaccines in cancer immunotherapy
Cancer vaccines, designed to activate the body's own immune system to fight against
tumors, are a current trend in cancer treatment and receiving increasing attention. Cancer …
tumors, are a current trend in cancer treatment and receiving increasing attention. Cancer …
[HTML][HTML] Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
L Decoster, I Wauters, JF Vansteenkiste - Annals of oncology, 2012 - Elsevier
The historical results of cancer vaccination for non-small-cell lung cancer (NSCLC) were
disappointing. In the current decade, however, new insights in the interaction between …
disappointing. In the current decade, however, new insights in the interaction between …